Literature DB >> 15742394

Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.

Shun-Yuan Jiang1, Jung-Mao Chou, Fur-Jiang Leu, Yu-Yen Hsu, Yu-Lung Shih, Jyh-Cherng Yu, Meei-Shyuan Lee, Rong-Yaun Shyu.   

Abstract

AIM: To analyze the expression of retinoic acid receptor responder 3 (RARRES3) protein in paraffin-embedded tissues of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), and the correlation of RARRES3 production with tumor differentiation.
METHODS: Expression of RARRES3 in tissues from 21 CC (10 well-, 7 moderately- and 4 poorly-differentiated) and 32 HCC was determined by immunohistochemistry.
RESULTS: Among 21 CC tissues, RARRES3 was detected in 8 (80%) of 10 well-differentiated tumors. Only 2 (18.2%) out of 11 tumors with moderate or poor differentiation showed positive RARRES3 expression. RARRES3 expression in well-differentiated CC was significantly higher than that in tumors with moderate or poor differentiation (Fisher exact test, P<0.01). Expression of RARRES3 was not different between early (I and II) and late (III and IV) stages of CC. Among 30 HCC tissues, 17 (56.7%) weakly expressed RARRES3 in HCC cells, and 25 (83.3%) normal tissues adjacent to HCC expressed the protein. RARRES3 expression was significantly decreased in HCC tissues compared to that in adjacent normal tissues (logistic regression analysis, OR = 0.27, 95% CI (0.11-0.62), P<0.01).
CONCLUSION: Expression of RARRES3 is positively correlated to well-differentiated CC, which supports the role of RARRES3 in malignant epithelial differentiation of the tumor. The decrease in RARRES3 expression in tissues of HCC and CC with moderate and poor differentiation suggests that altered RARRES3 expression may play a role in the carcinogenesis of the liver and biliary tract.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742394      PMCID: PMC4250783          DOI: 10.3748/wjg.v11.i7.948

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells.

Authors:  S L Huang; R Y Shyu; M Y Yeh; S Y Jiang
Journal:  Mol Cell Endocrinol       Date:  2000-01-25       Impact factor: 4.102

2.  Isolation, characterization, and chromosome mapping of a human A-C1 Ha-Ras suppressor gene (HRASLS).

Authors:  H Ito; H Akiyama; C Shigeno; T Nakamura
Journal:  Cytogenet Cell Genet       Date:  2001

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Suppression of the tumorigenicity of human hepatoma hep3B cells by long-term retinoic acid treatment.

Authors:  S L Hsu; H M Lin; C K Chou
Journal:  Cancer Lett       Date:  1996-01-19       Impact factor: 8.679

5.  Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma.

Authors:  C E Sever; J Locker
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

6.  Serum retinol and risk of hepatocellular carcinoma in patients with child-Pugh class A cirrhosis.

Authors:  Caterina Clemente; Silvana Elba; Gianpiero Buongiorno; Pasquale Berloco; Vito Guerra; Alfredo Di Leo
Journal:  Cancer Lett       Date:  2002-04-25       Impact factor: 8.679

Review 7.  Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment.

Authors:  Kunio Okuda; Yasuni Nakanuma; Masaru Miyazaki
Journal:  J Gastroenterol Hepatol       Date:  2002-10       Impact factor: 4.029

8.  Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.

Authors:  D DiSepio; C Ghosn; R L Eckert; A Deucher; N Robinson; M Duvic; R A Chandraratna; S Nagpal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12.

Authors:  K Husmann; C Sers; E Fietze; A Mincheva; P Lichter; R Schäfer
Journal:  Oncogene       Date:  1998-09-10       Impact factor: 9.867

10.  RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma.

Authors:  R-Y Shyu; S-Y Jiang; J-M Chou; Y-L Shih; M-S Lee; J-C Yu; P-C Chao; Y-J Hsu; S-W Jao
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more
  5 in total

1.  The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition.

Authors:  Yan Xu; Ting Chen; Degui Liao; Xiaoqin Wu; Yun Zhong; Shiming Liu; Hui Yang; Yuqiang Nie
Journal:  Tumour Biol       Date:  2016-03-08

2.  An Eight-CpG-based Methylation Classifier for Preoperative Discriminating Early and Advanced-Late Stage of Colorectal Cancer.

Authors:  Ji Hu; Fu-Ying Zhao; Bin Huang; Jing Ran; Mei-Yuan Chen; Hai-Lin Liu; You-Song Deng; Xia Zhao; Xiao-Fan Han
Journal:  Front Genet       Date:  2021-01-13       Impact factor: 4.599

3.  Induction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells.

Authors:  Fu-Ming Tsai; Rong-Yaun Shyu; Su-Ching Lin; Chang-Chieh Wu; Shun-Yuan Jiang
Journal:  BMC Cell Biol       Date:  2009-02-26       Impact factor: 4.241

4.  Long noncoding RNA HCP5 suppresses skin cutaneous melanoma development by regulating RARRES3 gene expression via sponging miR-12.

Authors:  Xihua Wei; Xuelian Gu; Min Ma; Chunxiang Lou
Journal:  Onco Targets Ther       Date:  2019-08-12       Impact factor: 4.147

Review 5.  Retinoic Acids in the Treatment of Most Lethal Solid Cancers.

Authors:  Lara Costantini; Romina Molinari; Barbara Farinon; Nicolò Merendino
Journal:  J Clin Med       Date:  2020-01-28       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.